WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical pres...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2018-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/3183 |
| _version_ | 1819290807544315904 |
|---|---|
| author | Maddalena Mazzucchelli Anna Maria Frustaci Marina Deodato Roberto Cairoli Alessandra Tedeschi |
| author_facet | Maddalena Mazzucchelli Anna Maria Frustaci Marina Deodato Roberto Cairoli Alessandra Tedeschi |
| author_sort | Maddalena Mazzucchelli |
| collection | DOAJ |
| description | Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features.
Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical presentation and prognosis and demonstrated therapeutic implications.
Treatment choice in Waldemstrom disease is strictly guided by patients age and characteristics, specific goals of therapy, necessity for rapid disease control, risk of treatment-related neuropathy, disease characteristics, risk of immunosuppression or secondary malignancies and potential for future autologous stem cell transplantation.
Therapeutic landscape has expanded during the last years and the approval of ibrutinib, the first drug approved for Waldenstrom Macroglobulinemia, represents an important step forward for a better management of the disease. |
| first_indexed | 2024-12-24T03:28:37Z |
| format | Article |
| id | doaj.art-748455d75cf0447f80dc0cbd686c7f6b |
| institution | Directory Open Access Journal |
| issn | 2035-3006 |
| language | English |
| last_indexed | 2024-12-24T03:28:37Z |
| publishDate | 2018-01-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj.art-748455d75cf0447f80dc0cbd686c7f6b2022-12-21T17:17:17ZengMattioli1885Mediterranean Journal of Hematology and Infectious Diseases2035-30062018-01-01101e2018004e201800410.4084/mjhid.2018.0041734WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATEMaddalena Mazzucchelli0Anna Maria Frustaci1Marina Deodato2Roberto Cairoli3Alessandra Tedeschi4Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, MilanoNiguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, MilanoNiguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, MilanoNiguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, MilanoNiguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, MilanoWaldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical presentation and prognosis and demonstrated therapeutic implications. Treatment choice in Waldemstrom disease is strictly guided by patients age and characteristics, specific goals of therapy, necessity for rapid disease control, risk of treatment-related neuropathy, disease characteristics, risk of immunosuppression or secondary malignancies and potential for future autologous stem cell transplantation. Therapeutic landscape has expanded during the last years and the approval of ibrutinib, the first drug approved for Waldenstrom Macroglobulinemia, represents an important step forward for a better management of the disease.https://www.mjhid.org/index.php/mjhid/article/view/3183Waldenstrom Macroglobulinemia, ibrutinib, chemoimmunotherapy, new agents |
| spellingShingle | Maddalena Mazzucchelli Anna Maria Frustaci Marina Deodato Roberto Cairoli Alessandra Tedeschi WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE Mediterranean Journal of Hematology and Infectious Diseases Waldenstrom Macroglobulinemia, ibrutinib, chemoimmunotherapy, new agents |
| title | WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE |
| title_full | WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE |
| title_fullStr | WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE |
| title_full_unstemmed | WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE |
| title_short | WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE |
| title_sort | waldenstrom s macroglobulinemia an update |
| topic | Waldenstrom Macroglobulinemia, ibrutinib, chemoimmunotherapy, new agents |
| url | https://www.mjhid.org/index.php/mjhid/article/view/3183 |
| work_keys_str_mv | AT maddalenamazzucchelli waldenstromsmacroglobulinemiaanupdate AT annamariafrustaci waldenstromsmacroglobulinemiaanupdate AT marinadeodato waldenstromsmacroglobulinemiaanupdate AT robertocairoli waldenstromsmacroglobulinemiaanupdate AT alessandratedeschi waldenstromsmacroglobulinemiaanupdate |